Abingdon Healt. Share Price (ABDX)

The share price may drop further on Thursday like many other small cap shares. What an opportunity to buy more!

Not small fry at all Nick.

I am certain the update will demonstrate further progress towards cashflow breakeven. That in itself is positive.

How the market reacts, of course, will depend entirely on how good that progress is and in particular, whether its enough to finally stave off concerns about a raise.

Hoping for a very positive update as I have just topped-up my ISA account, which together with my SIPP holding takes me to 200k shares. Small beer for some, but a significant investment for me!

Good luck and best wishes to all LTHs

Nick

On the TU, it really is worth listening to this again, particularly from 8.41-9.04 when Yates explains our revenue is weighted to H2 and is aiming for significant H2/H2 growth, and from 15.47 to 17.05 when he talks about cash burn, cost control and specifically says that even with a flat H2 equivalent revenue, “which is absolutely not where we’re going to be” we should see an improvement in cash.

So I’m expecting H2 revenue to at the very least higher than the £2.9m for H2 last year.

https://www.youtube.com/watch?v=4Z32joS9aD4

You did - Folium Science and their CrispR test for testing Salmonella in chicken flocks. So absolutely, it’s not just the home, but in the field and the farm.

And add to that the AMR concern. AMR is just as much fostered in animal populations because of anti biotic misuse as it is in humans, and there’s a real drive for accurate cheap testing methods to address that misuse. Again, great for us.

I post about Yates interest in HN51 not because I want to see another potentially more deadly pandemic, but because much of what can affect humans comes from animals. Currently the biggest HN51 concern is that the world doesn’t know how big the problem is because there’s no effective diagnostic surveillance. That presents an opportunity for us. And god forbid we did see a global rise, well if we had an accurate cheap diagnostic ready to go then our value might see rises like NCYT did with C19.